Table 3 Comparative analysis between patients’ groups with and without studied cytogenetic abnormalities regarding different parameters
Parameters | Cytogenetic abnormalities | Fisher exact test | |||||
Patients without the studied cytogenetic abnormalities (56) | Patients with the studied cytogenetic abnormalities (16) | P value | Sig. | ||||
N | % | N | % | ||||
Age (years) | < 1 | 4 | 7.1% | 4 | 25.0% | 0.335 | NS |
1–9 | 38 | 67.9% | 8 | 50.0% | |||
> 10 | 14 | 25.0% | 4 | 25.0% | |||
Sex | Male | 30 | 53.6% | 12 | 75.0% | 0.424 | NS |
Female | 26 | 46.4% | 4 | 25.0% | |||
Hepatomegaly | Absent | 30 | 53.6% | 2 | 12.5% | 0.053 | NS |
Present | 26 | 46.4% | 14 | 87.5% | |||
Splenomegaly | Absent | 32 | 57.1% | 4 | 25.0% | 0.228 | NS |
Present | 24 | 42.9% | 12 | 75.0% | |||
Lymphadenopathy | Absent | 12 | 21.4% | 4 | 25.0% | 1.000 | NS |
Present | 44 | 78.6% | 12 | 75.0% | |||
CNS infiltration | Absent | 52 | 92.9% | 12 | 75.0% | 0.207 | NS |
Present | 4 | 7.1% | 4 | 25.0% | |||
Aberrant expression in (IPT) | Negative | 40 | 71.4% | 12 | 75.0% | 1 | NS |
Positive | 16 | 28.5.% | 4 | 25.0% | |||
Risk classification | Standard risk | 32 | 57.2% | 0 | 0% | 0.009 | S |
High risk | 24 | 42.8% | 16 | 100% | |||
Outcome | Good | 40 | 71.4% | 4 | 25.0% | < 0.001 | S |
Bad | 16 | 28.5% | 12 | 75.0% | |||
Laboratory parameters | |||||||
Parameters | ttest | ||||||
Mean | SD | Mean | SD | Pvalue | Sig | ||
Hb (gm/dL) | 7.63 | 1.91 | 7.90 | 1.81 | 0.722 | NS | |
TLC (× 109/L) | 36.18 | 25.48 | 87.54 | 35.29 | < 0.001 | S | |
Platelets (× 109/L) | 78.71 | 29.46 | 50.38 | 23.32 | 0.017 | S | |
PB blasts (%) | 34.68 | 24.62 | 23.38 | 19.68 | 0.198 | NS | |
BM blasts (%) | 74.00 | 17.80 | 62.25 | 19.51 | 0.116 | NS | |
BM blasts at day 15(%) | 2.96 | 4.09 | 11.63 | 7.80 | 0.016 | S | |